Brand dynamics
Group Real-Time Dynamics And Cutting-Edge Information In The Field Of One Health
Time Posted：2022-03-04 16:57
Public Notice
Time Posted：2022-03-03 18:21
Recently, the Ministry of Industry and Information Technology and eight other departments jointly issued the "14th Five-Year Plan for the Development of the Pharmaceutical Industry" (hereinafter referred to as the "Plan"), which sets out development goals for the next five years and a long-term vision for the next 15 years.
Time Posted：2022-03-02 20:34
To control the spread of various mutant strains and the COVID-19 pandemic, countries around the world are actively carrying out large-scale booster vaccinations to consolidate the "first line of defense" against the epidemic. Many countries, including the US and UK, have taken the lead in promoting sequential booster immunization strategies using different technological approaches. On February 19, the State Council's joint prevention and control mechanism announced the deployment of sequential booster immunization, marking the beginning of heterologous booster vaccination in China.
Time Posted：2022-02-18 22:16
Based on existing COVID-19 vaccines, how can we improve the ability to fight against the Omicron variant? Sequential booster immunization (also known as "heterologous booster immunization") is considered one of the important areas of exploration. Recently, the interim primary data analysis of the Phase III clinical trial of "Recombinant Novel Coronavirus Fusion Protein Vaccine" (V-01), developed by Lizhu Antibody, an indirectly controlled subsidiary of Health and Wellness (600380.SH), has been completed, and key data has been obtained.
Time Posted：2022-02-17 19:16
Lizhu Group (000513.SZ) recently announced that its controlling subsidiary, Zhuhai Lizhu Monoclonal Antibody Biotechnology Co., Ltd. (referred to as "Lizhu Monoclonal Antibody"), in cooperation with the Institute of Biophysics, Chinese Academy of Sciences, has completed the interim primary data analysis of the Phase III clinical trial of its sequentially enhanced recombinant novel coronavirus fusion protein vaccine (referred to as "V-01") and obtained key data.
Time Posted：2022-02-17 10:10
On February 16, 2024, Gloryshe announced that the recombinant novel coronavirus fusion protein vaccine developed by Lizhu Dankang Biotechnology Co., Ltd. (Lizhu Dankang), a subsidiary of Lizhu Pharmaceutical Group Co., Ltd., a subsidiary of Jiankangyuan (600380.SH), has completed the interim primary data analysis of its sequential booster Phase III clinical trial and obtained key data.
Time Posted：2022-02-15 17:53
Recently, when accepting institutional investor research, Lizhu Group stated that the overseas Phase III clinical trial of its recombinant protein vaccine V-01 has completed the enrollment of subjects and the collection of clinical endpoint cases in some countries. The Phase III clinical trial conducted in Pakistan and Malaysia as a third-dose sequential booster based on an inactivated vaccine has achieved the interim analysis target set in the plan, and the interim data analysis is currently underway. The Phase III clinical trial of the basic immunization has also achieved the interim analysis target set in the plan, and the data is currently being actively cleaned and prepared for interim analysis.
Time Posted：2022-01-18 16:47
On the evening of January 14, 2022, Health Yuan (600380.SH) released its 2021 annual performance forecast. Health Yuan's 2021 net profit attributable to shareholders of the listed company is expected to reach 1.255 billion to 1.367 billion yuan, representing a year-on-year increase of 12% to 22%; non-net profit is expected to reach 1.141 billion to 1.237 billion yuan, representing a year-on-year increase of 18% to 28%; basic earnings per share are expected to be 0.65 to 0.7 yuan. The performance growth is in line with expectations.
Quick Navigation
+86 755-33268688 | Service Hotline
Official WeChat Official Account
Copyright © 2025 Joincare Pharmaceutical Group Industry Co., Ltd. ALL Rights Reserve.